← board
QTTB
Q32 Bio Inc.distress 6/10 · elevated risk$15.00-1%today-30% from 52w high
Dermatology 1Immunology / Inflammation 1
Lead: alopecia areata · target Complement
Revenue
$54M
Liquidity
$51M
Runway
1.9 yrs
Shares 1y
+39%
Price & events
+265.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.5%
1D
-1.4%
1W
+26.3%
1M
+131.5%
3M
+281.7%
6M
+541.1%
1Y
-53.6%
2Y
-87.2%
5Y
-92.8%
All
Overview
- Market Cap
- $254.38M
- Volume
- 95.46K
- 52 Week Range
- $1.63 – $21.38
- Total Shares
- 16.96M
- Float Shares
- 2.60M
- Short %
- 8.31%
- % Held by Insiders
- 4.24%
- % Held by Institutions
- 130.63%
- RVOL
- 0.05x
- Beta
- -0.27
Pipeline stages · 2 programs
bempikibart (ADX-914)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ADX-097Complement
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-06 | Phase 2 | bempikibart (ADX-914) | Alopecia Areata | 75 | active not recruiting |
| 2026-06 | Phase 2 | ADX-097 | IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy | 0 | withdrawn |
Catalyst news & presentations · 8
- first half of 2027trial initiationsecondaryPhase 3bempikibart · Advance into registration-directed programSEC 8-K
- mid-2026readoutPhase 2bempikibart · Topline results from SIGNAL-AA Phase 2a Part B trialSEC 8-K
- 2H'25readoutPhase 2ADX-097 · Renal basket Phase 2 Topline ResultsSEC 8-K
- 2025-11-28partnershipADX-097 · Sold to Akebia for $12M upfront/near-term payments and up to $580M in milestones plus royaltiesSEC 8-K
- 1H'25readoutPhase 2ADX-097 · Renal basket Phase 2 Initial DataSEC 8-K
- 1H'25trial initiationsecondaryPhase 2bempikibart · Initiate enrollment in SIGNAL-AA Phase 2a Part BSEC 8-K
- fourth quarter of 2024readoutPhase 2bempikibart · Topline data from Parts A and B of SIGNAL-AD Phase 2 trialSEC 8-K
- 2024-12-10enrollment delayADX-097 · Deferred enrollment into planned Phase 2 trial in AAV to focus on bempikibart AA and ADX-097 renal basket trialsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $39 (+158% upside) · 4 analysts
- 2026-07-13Wells FargoEqual-Weight → Overweight
- 2026-07-13OppenheimerOutperform
- 2026-05-22MizuhoOutperform
- 2026-05-18Cantor FitzgeraldOverweight
- 2026-05-05HC Wainwright & Co.Buy
- 2026-02-25HC Wainwright & Co.Buy
Competitors — Complement
- ARGXARGENX SE$54.3B · D0
Recent news
- 2026-07-22Q32 Bio Inc. (QTTB) corrects director grant to 10,826 stock options - Stock Titan
- 2026-07-22Q32 Bio Inc. (QTTB) corrects director stock option grant to 10,826 options - Stock Titan
- 2026-07-22Q32 Bio (QTTB) awards 10,826 stock options to director - Stock Titan
- 2026-07-22Q32 Bio (QTTB) corrects director’s 10,826 stock option award in Form 4/A - Stock Titan
- 2026-07-22Stock option grant for Q32 Bio Inc. (QTTB) director corrects prior award - Stock Titan
- 2026-07-22Q32 Bio (NASDAQ: QTTB) amends Form 4, granting 10,826 options - Stock Titan
- 2026-07-22Q32 Bio (QTTB) corrects director grant to 10,826 stock options - Stock Titan
- 2026-07-22Q32 Bio Inc. (QTTB) director awarded 10,826 options at $12.64 strike - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.